Tinzaparin - Clinical Resources
Tinzaparin Provincial Roll Out - September 27, 2022
Beginning Tuesday, September 27, all SHA sites will transition to using tinzaparin as the LMWH for most indications. Simultaneously, there will be a switch to using enoxaparin REDESCA (a biosimilar agent) for the remaining indications